Answers are grounded in this paper and cite their sources.
Introduction Women have poorer survival rates in advanced, metastatic or muscle-invasive bladder cancer (MIBC) than men. Enfortumab vedotin (EV) has changed the therapy and outcomes of MIBC and advanced bladder cancer dramatically. Therefore, the primary aim of this systematic review and meta-analysis was to evaluate sex specific differences in disease free (DFS), progression free (PFS), cancer specific survival (CSS), event free survival (EFS) and overall survival (OS) in those patients. Material and methods In October 2025, we performed a systematic literature search using MEDLINE via PubMed, Embase and Cochrane Library. This study was prospectively registered at PROSPERO (CRD420251064260). The detailed review protocol is accessible via CRD. Results The systematic literature search identified 249 studies, of which 17 fulfilled the inclusion criteria. No significant sex-specific difference was observed for OS (10 studies; HR 0.88; 95% CI 0.73–1.06; p=0.17; I²=32%). For PFS (8 studies), female sex was associated with a significantly better outcome (HR 0.67; 95% CI 0.57–0.78; p < 0.001; I² = 0%). Since the funnel plot suggested a significant publication bias, we conducted adjustment analyses, which yielded an HR of 0.41 (95% CI 0.24–0.57; p < 0.001). Only limited data was available for DFS, CSS and EFS. Overall, the risk of bias was assessed as moderate. Discussion There is very limited evidence that women have a significant better PFS than men during treatment EV for bladder cancer. Further studies should incorporate explicit sex-specific analyses, e. g. hormonal levels or genetic aspects, are needed.
No takes yet. Share an insight, caveat, or question.
Schneidewind et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: